N-(4-乙基苄基)乙胺 | 869941-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-乙基苄基)乙胺
• 英文名称: N-(4-ethylbenzyl)ethylamine
• 英文别名: N-(4-ethylbenzyl)ethanamine；N-[(4-ethylphenyl)methyl]ethanamine
• CAS: 869941-67-3
• 化学式: C₁₁H₁₇N
• mdl: MFCD04560112
• 分子量: 163.263
• InChiKey: QBYGBJWEJFPUOV-UHFFFAOYSA-N

物化性质

• 沸点：
  233.6±9.0 °C(Predicted)
• 密度：
  0.905±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  N-(4-乙基苄基)乙胺 反应 11.0h， 生成
  参考文献：
  名称：

  IMINE-TYPE QUATERNARY AMMONIUM SALT CATALYST, PREPARATION METHOD THEREOF AND USE THEREOF FOR PREPARATION OF POLYISOCYANATE COMPOSITION

  摘要：

  本公开涉及一种亚胺型季铵盐催化剂，其中催化剂具有如下式I所示的一般结构式；在该式中，R1和R2分别独立地选择自C1-C20直链烷基或分支的C3-C20烷基，以及C1-C20羟基烷基，C3-C8环烷基和芳基化烷基；R3是直链或分支烷基，环烷基或芳基；R4是氢，芳基，直链C1-C15烷基或分支的C3-C15烷基。还公开了一种制备该催化剂的方法以及由此制备的聚异氰酸酯组合物。该催化剂通过引入亚胺结构，在确保其高催化活性的基础上，具有高温分解和失活的特性，当应用于聚异氰酸酯的合成时，可以有效防止由于不受控制的反应引起的爆炸聚合风险。

  公开号：

  US20200377445A1

文献信息

• DHFR Enzyme Inhibitors
  申请人：Davidson Alan Hornsby

  公开号：US20090118311A1

  公开（公告）日：2009-05-07

  Compounds of formula (I) or (II) are dihydrofolate reductase inhibitors, useful for the treatment of, for example, cell proliferative diseases: wherein A and D are independently —CHR 7 — or —NR 7 —; E and G are independently ═CR 7 — or ═N—; each R 6 independently represents hydrogen or —OR 7 ; R 7 is hydrogen or C 1 -C 6 alkyl; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid which does not contain a carboxyl, or carboxyl ester group; Y is a bond, —C(═O)—, —S(═O) 2 —, —C(═O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n and p are independently 0 or 1, and Q, Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

  式(I)或(II)的化合物是二氢叶酸还原酶抑制剂，适用于治疗细胞增殖性疾病，其中A和D独立地为—CHR7—或—NR7—;E和G独立地为═CR7—或═N—;每个R6独立地表示氢或—OR7;R7是氢或C1-C6烷基;R1是羧酸基(—COOH)，或者是可由一个或多个细胞内羧酸酯酶水解为羧酸基的酯基;R2是天然或非天然α氨基酸的侧链，不含羧基或羧酯基;Y是键，—C(═O)—、—S(═O)2—、—C(═O)NR3—、—C(═S)—NR3、—C(═NH)NR3或—S(═O)2NR3—其中R3是氢或可选取代的C1-C6烷基;L1是式-(Alk1)m(Q)n(Alk2)p-的二价基团，其中m、n和p独立地为0或1，而Q、Alk1和Alk2如权利要求所定义;X1表示键;—C(═O);或—S(═O)2—;—NR4C(═O)—、—C(═O)NR4—、—NR4C(═O)NR5—、—NR4S(═O)2—或—S(═O)2NR4—其中R4和R5独立地为氢或可选取代的C1-C6烷基;z为0或1。
• PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Philips Oliver James

  公开号：US20100004250A1

  公开（公告）日：2010-01-07

  Compounds of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful, inter alia, in the treatment of proliferative diseases: wherein R 1 is hydrogen, or a (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 3 -C 6 )cycloalkyl group; R 2 is hydrogen, or an optionally substituted (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 3 -C 6 )cycloalkyl group; R 3 and R 3 ′ are independently selected from hydrogen, —CN, hydroxyl, halogen, optionally substituted (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl or (C 3 -C 6 )cycloalkyl, —NR 6 R 7 or C 1 -C 4 alkoxy, wherein R 6 and R 7 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl; ring A is an optionally substituted mono- or bi-cyclic carbocyclic or heterocyclic ring or ring system having up to 12 ring atoms; T is a radical of formula (II) R 4 R 5 CH—NH—Y-L 1 -X 1 —  (II) Wherein R 4 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R 5 is the side chain of a natural or non-natural alpha amino acid; and the linker radical —Y-L 1 -X 1 is as defined in the claims.

  式(I)的化合物是Polo-like激酶(PLKs)的抑制剂，可用于治疗增殖性疾病，其中R1是氢，或(C1-C6)烷基，(C2-C6)烯基，(C2-C6)炔基或(C3-C6)环烷基；R2是氢，或可选取代的(C1-C6)烷基，(C2-C6)烯基，(C2-C6)炔基或(C3-C6)环烷基；R3和R3'分别选自氢，—CN，羟基，卤素，可选取代的(C1-C6)烷基，(C2-C6)烯基，(C2-C6)炔基或(C3-C6)环烷基，—NR6R7或C1-C4烷氧基，其中R6和R7分别是氢或可选取代的(C1-C6)烷基；环A是可选取代的具有最多12个环原子的单环或双环碳环或杂环；T是式(II)的基团R4R5CH—NH—Y-L1-X1—  (II)其中R4是羧酸基(—COOH)，或可被一个或多个细胞内酯酶酶水解为羧酸基的酯基；R5是天然或非天然α氨基酸的侧链；连接基团—Y-L1-X1如权利要求所定义。
• HDAC INHIBITORS
  申请人：Davidson Alan Hornsby

  公开号：US20100010010A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L 1 , and X 1 are as defined in the claims.

  公式（I）的化合物抑制HDAC活性，其中A、B和D分别表示═C—或═N—；W是二价基团—CH═CH—或CH2CH2—；R1是羧酸基（—COOH），或者是可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基团；R2是天然或非天然α氨基酸的侧链；z为0或1；Y、L1和X1如权利要求中所定义。
• THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE
  申请人：Moffat David Charles Festus

  公开号：US20100010057A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C═O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P is optionally substituted C 1 -C 6 alkyl and Z is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; or Z is optionally substituted C 1 -C 6 alkyl and P is —(CH 2 ) Z —X 1 -L 1 -NHCHR 1 R 2 ; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; X 1 is (i) a bond; —NR 4 C(═O)NR 5 — or —NR 4 S(═O) 2 —; or except when X is —(C═O)— (ii) —C(═O)—, —S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z and L1 are as defined in the specification.

  化合物式(I)的复合物是P13激酶活性的抑制剂，并可用于治疗自身免疫性、炎症性和增殖性疾病，其中：s为0或1；U为氢或卤素；X为-(C═O)、一个可选取代的二价苯撑基、吡啶撑基、嘧啶撑基或吡嗪撑基基团，或一个键；P为可选取代的C1-C6烷基，Z为-(CH2)Z-X1-L1-NHCHR1R2；或Z为可选取代的C1-C6烷基，P为-(CH2)Z-X1-L1-NHCHR1R2；R1为羧酸基(—COOH)或一个酯基，该酯基可被一个或多个细胞内羧酸酯酶水解为羧酸基；R2为自然或非天然α-氨基酸的侧链；X1为(i)一个键；-NR4C(═O)NR5-或-NR4S(═O)2-；或除非X为-(C═O)- (ii) -C(═O)-、-S(═O)2-或-S(═O)2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z和L1如规范中定义。
• ADENINE DERIVATIVE AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER
  申请人：Moffat David Festus Charles

  公开号：US20100035901A1

  公开（公告）日：2010-02-11

  The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R 1 , R 2 , L 1 , Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

  该发明提供了一种化合物，其为（a）公式（I）的氨基酸衍生物或其互变异构体，或（b）其药学上可接受的盐，N-氧化物，水合物或溶剂化物：其中R1，R2，L1，Het，A，x，y和W如此定义。该化合物在治疗由HSP90介导的疾病方面具有用途。